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COMMENTARY

Prospects for subunit vaccines: Technology advances resulting in efﬁcacious antigens
requires matching advances in early clinical trial investment
Siobhan McClean
Centre of Microbial Host Interactions, Institute of Technology Tallaght, Dublin, Ireland

ABSTRACT

ARTICLE HISTORY

With the continued march of antimicrobial resistance, a renewed impetus for better vaccines has been
heralded. Identiﬁcation of potent subunit vaccines has been greatly facilitated by recent developments in
reverse vaccinology and proteomics strategies. There are a range of antimicrobial resistant bacterial
pathogens that could be targeted by potent vaccine antigens identiﬁed within the coming years.
However, cost is a signiﬁcant hurdle in progressing lead antigen candidates to clinical trials. In order for
novel vaccine technologies to realize their clinical potential, there is a requirement to improve investment
and incentives to expedite the development of vaccines that are apparently efﬁcacious in preclinical trials.

Received 7 July 2016
Accepted 19 July 2016

The global problem of antimicrobial resistance (AMR) is
fast becoming one of the major scientiﬁc and health issues
of modern times. Globally, drug-resistant infections are
responsible for several hundred thousand deaths annually.
By 2050 that ﬁgure could be more than 10 million. Of particular concern is the mounting prevalence of infections
caused by multidrug resistant (MDR) Gram-negative bacteria. In particular, the human pathogens Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii
have been singled out as “serious threats to human health”
by the EU, the US Centers for Disease Control and Prevention, and the World Health Organization due to the existence of extremely drug resistant strains. Other multidrug
resistant pathogens, such as members of the genus Burkholderia also cause chronic life-threatening infections and their
eradication is very challenging.
In the ﬁnal report prepared by the Review of Antimicrobial
Resistance,1 one of the key recommendations for reducing the
demand for antibiotics was the promotion of the development
of vaccines and alternatives. In particular, a renewed impetus
for early stage vaccine research was recommended. It is widely
accepted that vaccines do not induce selection pressures on the
environment and consequently do not contribute to antimicrobial resistance.2 Their impact on public health has been tremendous, with global reductions in both mortality and morbidity of
infectious diseases. For example, recent data from the World
Health Organisation on polio eradication highlights the effectiveness of vaccination (http://www.polioeradication.org/Data
andmonitoring/Poliothisweek.aspx). This paralysing and
potentially fatal infectious disease is now endemic in only 2
countries, Afghanistan and Pakistan, and the number of countries that reported no cases of polio in 2015 increased on previous years. When compared with data from 30 y ago, the impact
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of vaccination is unequivocal. It is estimated that there were
over 394,000 cases of poliomyelitis worldwide in 1987, before
the global eradication effort began, while there were only 29
cases of wild-type polio reported globally in 2015 (www.polioer
adication.org). The efforts of the Global Alliance for Vaccines
and Immunisation (GAVI) contribute to this effort directed
toward reducing childhood mortality by increasing access to
immunisation in poorer countries.

Recent advances in subunit vaccine identiﬁcation
Despite these unquestionable successes to date, there is a need
for vaccines that speciﬁcally target antibiotic resistant bacterial
infections. Subunit vaccine antigens have potential as safe, scalable, efﬁcacious vaccine candidates. A number of strategies
have been devised to identify novel vaccine antigens. Rappuoli
et al. pioneered the use of reverse vaccinology to identify novel
antigens against Neisseria meningitides serogroup B. They
sequenced the genome, identiﬁed 350 surface proteins and
administered them to mice to identify those that were immunogenic.3 This predictive approach which has revolutionised vaccine antigen discovery is based on the assumption that proteins
that induce protective immunity are located outside the cell
membrane and therefore possess signal sequences.4 The
recently licensed MenB vaccine (BexseroÒ ) was developed following this approach and should have a real impact on meningococcal disease caused by MenB, which had not been covered
in previous meningococcal vaccines.5 Immunoproteomics
approaches are also being used to identify novel antigens that
elicit potent immune responses, but when used in isolation,
they have limitations and may miss some key antigens.6 For
example, the prophylactic Bordetella pertussis antigen FHA
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(ﬁlamentous hemagglutinin), a component of all licensed
whooping cough vaccines, was undetectable in 2 immunoproteomic studies.7, 8
Historically, efﬁcacious vaccine antigens are involved in host
cell attachment, such as the B. pertussis acellular vaccine. The
current approved vaccine contains 5 B. pertussis antigens: pertussis toxoid, ﬁmbriae 2 and 3, pertactin, together with the
aforementioned FHA. These antigens are all virulence factors
involved in bacterial attachment,9 thereby highlighting the
potential of adhesins and bacterial proteins involved in interactions with host cells as potent vaccine antigens. Indeed, the 4
main components of the MenB vaccine are also involved in the
virulence of N. meningitides, including host cell attachment
and serum resistance.10,11 Identiﬁcation of previously undiscovered adhesins or other proteins that are used by bacteria to
attach to host tissue has the potential to unearth efﬁcacious vaccine subunit antigens. Recent advances in proteomics have
enabled the rapid identiﬁcation of proteins that are involved in
the direct interactions between the host cells and bacterial
pathogens. In particular the sensitivity of mass spectrometry
(MS) based techniques has been invaluable in the identiﬁcation
of adhesins that had not been previously identiﬁed. We developed a proteomic platform technology to identify bacterial
adhesins involved in host cell attachment (see below) and have
proven our approach in preclinical studies.12,13 Lead candidates
demonstrated efﬁcacy in preclinical trials against 2 recalcitrant
infections.
The proteomic approach
We have a particular interest in pathogens in the genus Burkholderia, which are highly antibiotic resistant and cause challenging, difﬁcult to treat infections. One subgroup of species
within this genus, Burkholderia cepacia complex (Bcc), causes
opportunistic infections in people with cystic ﬁbrosis and in
certain immunocompromised patients. Bcc is very difﬁcult to
eradiate due to both inherent and acquired antibiotic resistance
mechanisms and consequently is a suitable model pathogen for
investigating our subunit vaccine discovery approach. Despite
it having a complex genome of 8Mb, relatively few adhesins
had been identiﬁed using mutagenesis methods.14-17 We initiated a proteomic examination of the adhesins involved in
attachment to host lung epithelial cells.12 This involved probing
2-dimensional blots prepared from bacterial membranes with
lung epithelial cells to facilitate interaction of the human host
cells with the separated bacterial proteins. The bacterial proteins which were highlighted as interacting with host cell proteins were identiﬁed by Matrix-assisted laser desorption/
ionisation (MALDI-ToF) MS. In this way, we reproducibly
identiﬁed 14 proteins used by Burkholderia to attach to host
epithelial cells.12 Most of these proteins had not previously
been identiﬁed as having involvement in host-pathogen interactions involving Burkholderia species. The outer membrane
protein OmpW was among those identiﬁed as being involved
in the attachment of 2 Bcc species, B. multivorans and B. cenocepacia. This protein had been previously identiﬁed as an adhesin in Vibrio cholera18 but was not previously associated with
pathogenesis in Bcc. Another protein reproducibly identiﬁed in
our analysis was the 29 kD protein, Linocin, which had been
previously shown to be immunogenic in Mycobacterium

tuberculosis, stimulating potent T-cell responses,19 but, again,
had not been previously identiﬁed as having a role in host cell
attachment or Bcc pathogenesis. We had previously shown that
9 of the proteins identiﬁed in our Cell-blot were immunoreactive in an earlier study, in which 2-dimensional blots of bacterial membrane preparations were probed with serum from Bcc
infected cystic ﬁbrosis patients.20 This was an important point
to establish as it highlighted that these proteins, identiﬁed from
microbial cultures, were indeed expressed during human infection and were immunoreactive. As a proof of concept study to
test our Cell-blot strategy, we selected 2 of the proteins involved
in host cell attachment for pre-clinical vaccine efﬁcacy assessments. We recombinantly expressed both proteins, Linocin and
OmpW in E. coli, puriﬁed them and removed endotoxin.
Immunisation with the individual proteins showed protection
against challenge, as measured by several log reductions in bacterial lung counts for the 2 most clinically relevant Bcc species,
B. multivorans and B. cenocepacia.12
Burkholderia pseudomallei is another member of the
Burkholderia genus and is the causative agent of melioidosis, a
tropical disease endemic in Southeast Asia and Northern Australia. As with Bcc, these infections are difﬁcult to treat and
cause chronic and often fatal infections in the host.21 Vaccination of susceptible populations would have much more potential in terms of reducing the morbidity and mortality of this
life-threatening infection. To date, there are no approved vaccines to protect against melioidosis. As a further evaluation of
our proteomic Cell-blot strategy, we assessed whether B. pseudomallei OmpW would have potential as a vaccine candidate
against B. pseudomallei. A closely related homolog of B. pseudomallei OmpW (B. thailandensis OmpW) had previously
been shown to be immunoreactive in an immunoproteomic
analysis 22 and, with this in mind we examined the potential
of B. pseudomallei OmpW to protect mice against lethal infection. Immunisation with endotoxin-free OmpW protein, adjuvanted with monophosphoryl lipid A, protected challenged
mice with 75% survival relative to 25% in unimmunised controls. Furthermore, the protection in a genetically resistant
mouse model, C57BL/6, against a lethal B. pseudomallei infection lasted for up to 80 days, surpassing the efﬁcacy of the live
attenuated strain (2D2) conﬁrming that the protection by this
protein was not restricted to a single MHC haplotype.13 This
level of protection from a single antigen is notable. Multiple
subunit antigens would be likely to give optimal long-term
protection in the human population and additional studies are
warranted to identify additional antigens which might be
components of a multi-subunit B. pseudomallei vaccine. Nevertheless, the fact that these antigens identiﬁed by our proteomic Cell-blot strategy showed considerable protection against
2 distinct Burkholderia infections substantiates our strategy to
identify potent subunit antigens.

Future prospects
Antigen identiﬁcation is the ﬁrst step in a lengthy development
process to obtain a licensed vaccine. Their safety, stability, formulation and identiﬁcation of optimal adjuvant are other noteworthy steps in the developmental path. Recent advances such
as a systems biology approach or “systems vaccinology”
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approach to investigate immunity will help elucidate the adaptive responses to vaccination in immunised cohorts23 and
should both enhance and expedite vaccine development. Ultimately, all vaccines, despite their potential in preclinical models
and/or known correlates of protection, must be evaluated in
human trials. Progression of vaccine antigens that have shown
good efﬁcacy and safety in animal models to human trials is a
substantial hurdle. In particular, the leap in costs from preclinical to clinical trials is considerable and beyond the resources of
many of the academic researchers engaged in the identiﬁcation
of potent vaccine antigens. There are considerable risks associated with the development of vaccines, as with any new drug,
making investors understandably cautious. Indeed, efﬁcacy trials with vaccines can take much longer than traditional clinical
trials for new therapies, as a proportional reduction in infection
rate between vaccinated and non-vaccinated people must be
determined. In rarer infections, this can lead to a considerably
prolonged developmental path. Due to these risks, most investors or potential licensees are reluctant to engage with any vaccine development project in advance of Phase 1 human data.
Yet, by our estimation, the most limited phase 1 study on a subunit vaccine antigen would cost in the region of €400 K, including GMP manufacture. This results in a very tight bottle neck,
with the consequence that the process of identifying better,
more potent antigens is at risk of becoming a mere academic
exercise, unless there is a real global will to support more early
stage clinical trials. These supports might include an international fund speciﬁcally targeted at early vaccine clinical trials.
The Strategic Multi-Attribute Ranking Tool for Vaccines or
“SMART Vaccines” tool developed by the Institute of Medicine
can help decision makers prioritize vaccines in development
which is welcome.24 If vaccines are to be one of the weapons in
the armoury against drug resistant infections, companies could
also incentivised to invest in early stage clinical trials in order
to bridge the gap between preclinical vaccine research and
human efﬁcacy and safety data. These kinds of incentives at
government level could include tax incentives, enhanced patent
protection and marketing rights or ﬁnancial subsidisation of
SMEs or pharmaceutical companies involved in early stage vaccine clinical trial research. Furthermore, a national or international agency that streamlines GMP manufacture and clinical
trial testing of vaccines would be a signiﬁcant vehicle for the
expedient development of vaccines against antimicrobial resistant bacteria.
In summary, there have been substantial advances in the identiﬁcation of efﬁcacious vaccine candidates in the past decade.
Progression of the best of these toward clinical trials will be the
next major challenge in developing better human vaccines.
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